Hanger, Inc. (HNGR) CEO Vinit Asar on Q3 2020 Results – Earnings Call Transcript

Start Time: 08:30 January 1, 0000 9:08 AM ET

Hanger, Inc. (NYSE:HNGR)

Q3 2020 Earnings Conference Call

November 05, 2020, 08:30 AM ET

Company Participants

Vinit Asar – President and CEO

Thomas Kiraly – EVP and CFO

Seth Frank – VP, Treasury and IR

Conference Call Participants

Brian Tanquilut – Jefferies

Larry Solow – CJS Securities


Greetings, and welcome to Hanger’s Third Quarter 2020 Earnings Call. All participants will be in listen-only mode. [Operator Instructions]. As a reminder, this conference is being recorded. Today, we will have prepared remarks, followed by a Q&A period. Instructions for questions and answers will be provided after the formal presentation.

It is now my pleasure to introduce your host, Seth Frank, Vice President of Treasury and Investor Relations. Sir, you may begin your conference.

Seth Frank

Good morning. Thank you. Welcome to Hanger’s third quarter 2020 earnings conference call. With us today are Vinit Asar, Hanger’s President and Chief Executive Officer; and Thomas Kiraly, Executive Vice President and Chief Financial Officer.

Some of the information discussed today will include forward-looking statements in the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties that could cause Hanger’s actual results to materially differ from those we discuss today. Those risks include, among others, matters we have identified in the forward-looking statements portion of our latest earnings release and in our filings with the SEC. Hanger disclaims any obligation to update forward-looking information discussed on this call.

And now, I’d like to hand the call over to them.

Vinit Asar

Thanks, Seth. Good morning and thank you all for joining us Hanger’s third quarter 2020 earnings conference call. During the third quarter, our patient volumes demonstrated a continued recovery and combined with our cash preservation measures, contributed to a favorable earnings and cash flow performance despite the continuing pandemic.

In response to this positive trend, along with our strengthened liquidity position, and in order to enter 2021 with momentum, we restored employee salaries and welcomed back furloughed employees as of October. I want to express my appreciation to Hanger’s employees for the high quality of patient and customer care provided during these times and also for enabling us to achieve the strong financial and operational position we are in today.

The better volume trends during Q3 resulted in a further narrowing of year-over-year revenue declines. We acknowledge that while the ultimate length of the pandemic is not fully known, especially given the current resurgence of infections, we are well positioned to meet the return of normalized volume, and pick up where we left off on organic and acquired growth strategies.

Net revenue for the third quarter totaled $256.6 million, a decrease of 8% or $23 million compared to the same period of 2019. Total adjusted EBITDA in the quarter was $27.9 million, which reflects a decrease of $4.8 million. Tom will provide more details, but even as we had partially restored salaries during the third quarter, our efforts on cost containment and capital preservation continued to insulate the company from the impact of lower year-on-year revenue.

In the patient care segment, third quarter appointment volume declined 16% compared to 33% in the second quarter, a meaningful improvement. Same clinic net revenue on a day-adjusted basis declined 10.3%, a marked improvement from the 18.7% decline reported in the second quarter.

A variety of factors, including the comfort, ability and willingness of patients to seek O&P care remains the primary gating factor in the pace of recovery. Judging by the sequential uptick in patient appointment volumes during Q3 and the direct feedback we received through our Net Promoter Score process, our patients are getting increasingly comfortable with the safety protocols we have in place within our clinics.

Our overall Net Promoter Score for patient care remains strong at 85.5 despite the challenging environment. Excluding acquisitions, our prosthetic business demonstrated a continued resilience, declining only 8.9% compared to the same period last year, generally in line with Q2 of 2020, while orthotics demonstrated a pronounced sequential recovery, declining by 11.8% in Q3 compared to 30.4% in Q2 of 2020.

Custom orthotics categories for spinal and cranial applications remain strong. Shoes and inserts remain relatively depressed compared to other orthotic categories. Patient care segment EBITDA margins grew in the quarter, boosted by strong collections, resulting in lower disallowed revenue and the previously stated impact of the personnel cost actions.

Our revenue cycle team continues to demonstrate success, working with the payer community to ensure we are generating above market results and cash collections during these uncertain times. Our products and services segment also performed better in the third quarter.

Total segment net revenue declined 9.7% in the third quarter. This is compared to a 24.7% decline in the second quarter. We are pleased with the performance of the distribution business and its recovery through this year.

While some of this improvement is due to overall industry recovery, we have confidence that our distribution subsidiary continues to gain new customers and market share, based on our superior product offerings as well as strong customer satisfaction and service.

Our therapeutic solutions subsidiary was stable. We continue to monitor the skilled nursing market closely, but believe we have strengthened our portfolio of offerings to be valuable and differentiated as that market settles. In all, we think third quarter and year-to-date business trends point to a full recovery and return to growth in 2021, barring a significant setback related to the current COVID-19 resurgence.

The restoration of full salaries, even ahead of normalized volumes, is critical for the welfare of our people and the long-term benefit of the company and all our stakeholders. Hanger has invested significantly in our human capital, so it is imperative to protect our most critical assets for the long term.

Our mantra during COVID; be safe, be kind, be strong, which I have shared with you before, has been an effective true north for us. Safety of our employees and patients remains an absolute priority and a critical element of our success to date.

As a healthcare services company, we are uniquely positioned to leverage our internal resources for which we had the foresight to move quickly in January to organize and plan for the pandemic financially and operationally.

As a result, we have been able to keep most of our clinics open, provide a safe environment for patient care and keep our employees safe with minimal disruption from coronavirus infection. We believe this will allow us to pick up where we paused in our strategic and operational growth journey, intact as an organization and prepared to move forward.

As a result, we recently announced new leaders for our two business segments. We promoted Regina Weger, a 20-year Hanger veteran and former President of our O&P distribution business to the President of our Products & Services segment.

As you know, our distribution business has grown significantly over the last several years. This is due in large part to Regina’s leadership and extensive knowledge of the O&P industry. Regina will expand this success with the cohesive strategy and a focus on growth, leading the Products & Services segment.

Secondly, we welcomed Pete Stoy to the position of Chief Operating Officer at Hanger, responsible for the patient care segment. As a growth-oriented leader, Pete brings a wealth of healthcare industry experience to Hanger, possessing deep relationships at medical systems across the United States.

Pete comes from Sodexo Healthcare Services, managing their East Coast region. Prior to that, he spent 17 years between McKesson and Cardinal Health, leading large-scale commercial and operational teams. Pete’s growth orientation, his skill set and experience across a number of healthcare businesses will be of tremendous value as we scale up in the coming years.

Finally, at the Board level, we expanded our expertise with the addition of Dr. Mark Jones to the Hanger Board effective in late September. Dr. Jones is a practicing orthopedic surgeon at OrthoVirginia, Virginia’s largest provider of orthopedic care and therapy.

He has more than 20 years of experience in a surgical field linked closely to O&P, and he brings invaluable expertise and first-hand knowledge of patient care to our Board. He also served as Chief of Orthopedic Surgery at Johnston Willis Hospital in Richmond, Virginia.

During the quarter, our Clinical and Scientific Affairs team continued expanding our O&P outcomes research agenda to help illustrate the significant value of O&P services to healthcare decision-makers from a health economics perspective.

The recently peer-reviewed and published IMPACT 2 study analyzed patients with lower limb amputations. The study determined that individuals receiving a prosthesis earlier in the rehabilitation period, specifically within three months following amputation, were almost 50% less likely to require an ER visit, and were significantly less likely to experience a fall.

Our research team highlights the long-term health outcome, quality of life and cost benefits of earlier prosthesis intervention in lower limb amputations. We are also expanding our research agenda to include the assessment of O&P technology as we increase the body of knowledge to help clinicians make more informed decisions about the relative benefits and comparability of componentry from different manufacturers, such as the outcomes associated with microprocessor controlled knee models.

To that end, we expect to see the publication of our OASIS 1 study in a leading peer-reviewed research journal. This study provides an unbiased head-to-head comparison of four different microprocessor knees from four different manufacturers for various patient populations.

As the leading provider of O&P services, we are conducting clinical research to better serve our patients through informed clinical decision-making, agnostic to manufacturer or specific underlying technology. It is these types of studies that we share with our referral sources and peer community to continue to strengthen and expand the clinical partnerships that are essential for quality patient care.

As the O&P industry continues to navigate the challenges posed by the pandemic, Hanger is at the forefront of best practices in the areas of patient care, clinical outcomes, pandemic-related safety protocols, evolving payer requirements and technology assessments. To that end, we have begun to host roundtables with industry leaders to ensure that we are staying abreast of industry trends and maintaining key relationships.

We are also recommencing our M&A program and are pleased with the quality and depth of the pipeline. The pandemic has further demonstrated challenges and stresses of running a local independent O&P practice. It has likely exacerbated the desire for some of these businesses to join Hanger based on their relevant expertise and support that we bring to bear, allowing clinicians to focus on what they do best, which is patient care.

So in summary, we are very pleased with the manner in which we have navigated what has been a year of unprecedented challenges. We accomplished our near-term goals, specifically preserving liquidity, thanks to the significant efforts and sacrifices of our employees, assistance from the CARES Act as well as an outstanding effort by our revenue cycle management and financial teams.

We believe that we have placed Hanger in a position of strength to navigate the post-pandemic world and pick up on a strong growth trajectory as COVID-19 subsides in 2021. Thank you for your time and interest in Hanger.

Now, Tom will discuss the numbers in more detail. Tom?

Thomas Kiraly

Thanks, Vinit. As the results demonstrate, during the third quarter, Hanger continued to perform well despite the adverse business conditions caused by the COVID-19 pandemic. As discussed in our August investor call, our primary objectives during the current year have included the accumulation of capital in order to position Hanger for the effects of a prolonged pandemic as well as a focus on preserving our personnel and clinical capacity so that we can resume our growth and expansion in 2021. We believe we achieved those objectives in the past quarter.

During this most recent period, Hanger produced 256.6 million in revenue, which reflected a 23 million or 8.2% decrease as compared to the same period last year. Adjusted EBITDA was 27.9 million as compared to 32.6 million. We benefited from approximately 16 million in temporary labor and operating cost reductions during the quarter.

With this performance for the year-to-date, Hanger stands at 723.8 million in revenue and 69.7 million in adjusted EBITDA, which reflects a 9.2% decline in revenue and a 14.9% decrease in adjusted EBITDA as compared with the first nine months of 2019. Our year-to-date results have benefited from a total of approximately 51 million in temporary cost reductions.

In the third quarter, the decline in revenue was primarily driven by an $18.3 million decrease in our patient care segment. Since our peak decline of approximately 40% in April, patient appointment volumes in this segment have gradually improved each month to a decline of 13% in September and an average decline of 16% for the full third quarter.

As Vinit shared, improved orthotics volumes were the key service area that contributed to the sequential increases in revenue from the second quarter. Nevertheless, prosthetics continues to constitute an increasing portion of our revenue mix. During the third quarter, prosthetics accounted for 55.5% of our revenue in 2020 as compared with 54.8% at the same time last year.

Given the higher relative reimbursement rate of prosthetic devices, their increase as a percentage of our revenue contributed to a moderation of the patient appointment decline effect on our revenue, as the segment was down 10.3% in same clinic revenue on the 16% decrease in patient appointments during the quarter. The company’s net revenue in this segment also continued to benefit from favorable collection trends.

Due to a strong performance by our revenue cycle management team, disallowances and patient non-payment fell to 4.6% of gross charges in the quarter, which compared favorably to the 5.8% we reported during the same period last year. This continued to be a key contributing factor to the company’s favorable cash flow and working capital trends as it has been throughout 2020.

While our products and services segment also continued to be affected by the pandemic, in a manner similar to the patient care segment, we also saw some strengthening of volumes in this area of our business. Revenues in this segment declined by 4.7 million or 9.7% in the third quarter as compared with the same period in 2019. This reflected a significant improvement from the 24.7% decline reported in the second quarter. Within this segment, distribution services declined by 10.8% and therapeutic solutions decreased by 6.6%.

To focus a little deeper on the company’s cost reductions. During the third quarter, in addition to an $11 million decrease in materials costs, we realized approximately $11 million in savings from exempt salary reductions, employee furloughs, reduced employee hours and associated payroll taxes. We also saved an approximate 5 million from reductions in travel, professional fees, advertising, bad debt and other expenses.

As we discussed in our second quarter financial filing and conference call, when considering these savings, it is important to recognize that they are temporary in nature. Our multi-quarter plan for addressing the COVID-19 pandemic was designed to enable the company to build the financial resources to withstand and extend the pandemic and to preserve the Hanger team at its capacity to see and treat patients in the coming year.

By September 30, we had completely restored our wage reductions and returned all but a small number of our furloughed positions to active status. As a result, we would estimate that the company will incur a sequential increase of approximately 11 million to 14 million in its salaries and operating expenses in the fourth quarter as compared with the third quarter.

While we will continue to remain focused on managing our expenses during this demanding time, we think it’s highly important that the sequential increase in our cost structure be taken into account when estimating the company’s earnings for coming quarters.

Before I turn to cash flows, I’d like to take a moment to discuss the progress we’ve made this year in our supply chain strategy. Despite the need to delay our technology investment relating to the primary procurement systems, in the second and third quarters, we did proceed with the build-out of our new distribution facility in the Atlanta area, and we are now in the process of also completing the implementation of the associated systems necessary to operate that facility.

Of the 22.5 million we’ve expended in capital and program equipment expenditures in 2020 to date, just under 7 million of that related to our work on this new distribution center. Additionally, it’s important to note that we have benefited from approximately 3 million for the year-to-date in savings derived from successful freight provider negotiations, and from changes in certain of our supply chain operating practices. This program and the people who lead it have done a tremendous job progressing this critical agenda despite the distraction and pressures caused by the pandemic.

Now, I’ll provide you with some further discussion regarding our cash flow. During the past three months, through favorable operating results and working capital actions, we were able to generate strong operating cash flows and accumulate further capital resources.

Our operating cash flow was 45.2 million in the quarter and grew to a level of 125.2 million for the year-to-date. This reflected an increase of 105.3 million for the year-to-date as we produced 19.9 million of operating cash flow in the first nine months of 2019. We have benefited from strong improvements in accounts receivable collections, which reflected a four-day improvement in DSO in the third quarter as compared with the same period last year.

During the year, increases in operating cash flow have also been driven by favorable trends in inventories and accounts payable terms, the receipt of 24 million in funds during the second quarter from the CARES Act and deferrals of compensatory payments, including current year payroll taxes.

These various actions have decreased our current investment in net working capital, excluding cash and current portion of debt, by 70.4 million when comparing our balances at September 30 of this year with the same date last year.

As we discussed on the second quarter call, as the company returns to a more normal level of operation in 2021, we’ll likely need to reinvest this approximate amount of cash to reestablish working capital, and it will have an equal and offsetting effect in our operating cash flows next year.

Nevertheless, due to these significant measures we accumulated 242.3 million in cash and available capacity under our revolving credit facility as of September 30. This reflected an increase of just under 40 million during the quarter and 111 million or 84% since March 31.

We believe having access to these financial resources has placed us in a position to be able to endure the consequences of the pandemic and perhaps even more importantly, it has enabled us to move from being on defense to offense as we approach the new year.

After considering our retained cash, net indebtedness was 381.7 million at the end of the quarter and reflected a net leverage ratio of only 3.4x trailing 12 months adjusted EBITDA despite the adverse effects of the pandemic.

Now, I’ll provide you with some brief comments regarding our trends as we close out the current year and enter 2021. While we did continue to benefit from a gradual sequential increase in patient appointments in the third quarter, we would encourage a cautious near-term view on volume trends due to the recent significant increases in infection rates.

While we cannot be certain as to how these increases will affect the behaviors of our patients, our belief is that it would be best to remain careful in assuming further improvement in patient appointments for the time being. It is also due to this continuing uncertainty that we have chosen to not provide guidance at this time.

In summary, from a financial perspective, due to the continued execution on our plan, we were able to sustain the positive cash flow and working capital momentum we commenced in the second quarter, and the company has continued to build the financial resources necessary to position it well for a resumption of its business in 2021.

With that, I’ll turn the call back over to the operator to open it up for any questions you may have.

Question-and-Answer Session


Thank you. We will now begin the question-and-answer session. [Operator Instructions]. And the first question will be from Brian Tanquilut with Jefferies. Please go ahead.

Brian Tanquilut

Hi. Good morning, guys. Congrats on the good quarter. I guess, Tom, I’ll start with the comments you just made towards the end of your prepared remarks. As we think about the sequential trend, right. So am I right in thinking that your employees are back to full salary and full hours, so we should see an uptick sequentially in expenses and then essentially flattening revenue just because of your cautiousness in COVID? And then kind of like build from that as we think about 2021, sounds like using the Q4 exit run rate as the baseline for growing ’21, is that the right way to think about that?

Thomas Kiraly

Yes. I think a number of the elements that you shared are on point, but just to clarify a bit. So yes, on the expense side, we do think an increase in cost structure of 11 million to 14 million. On the revenue side, it’s just very difficult to predict. We are concerned about the increase in infections and the fact that that may cause the recovery to stay pretty much flat with where Q3 was, which would mean that Q4 would not at all be comparable to last year’s Q4. When you go to next year, it’s – at this point, we’re somewhat more positive in our view. We do think we’re seeing a big search here in the winter from COVID, and it could have an additional effect on the business in the near term. But we’d like to believe that the company is in a good position to benefit as we go into 2021, and the country moves more to a recovery from this virus.

Brian Tanquilut

And I guess a follow-up to that, Tom, in past quarters that we’ve talked about this, you guys felt confident that 2021 would look a lot like what your pre-COVID 2020 outlook would have been, right. So do you still believe that that’s the case?

Vinit Asar

Yes. Hi, Brian. This is Vinit.

Brian Tanquilut

Hi, Vinit.

Vinit Asar

Yes, we do. Hi, Brian. We do believe that’s the case because if you think back when we began 2020, we had all the pieces in place. We had the strategy set. We had the people set. We were feeling pretty positive about the momentum coming into 2020 and then COVID hit. So as this pandemic subsides, we think we’ll pretty much pick up where we left off in terms of that growth trajectory, because all those pieces are in place and we’re just stronger today from a liquidity perspective. So it helps out.

Brian Tanquilut

Just to that point on the liquidity perspective, right, so it sounds like you’re back into considering acquisitions. So if you don’t mind just walking us through how you’re thinking about deal flow, data pacing and also like what characteristics or what types of assets are you interested in at this point?

Vinit Asar

Sure. So, we certainly have been engaged in a fair amount of discussions with potential sellers of these smaller O&P businesses, both local businesses as well as the regional businesses, and the criteria we look at really is a combination of things. It’s the geography of where these businesses are located. We look at things like what is their compliance to billing and regulations. We look at the size. We also look at the quality of the team. For the most part, we know who these clinicians are. We know, in general, the reputation of the team. So we look at the quality and we look at the cultural fit, how will these businesses fit in with Hanger and the desire to join Hanger? And then the way we look at success factors, Brian, for us, a transaction is successful when we know that we’ve retained all the clinicians, they’re productive. We’ve had a smooth integration. The new team that’s coming in wants to take on and take advantage of the processes and the extensive resources we have so that they can focus on patient care. So during the first year, it’s about making sure the transition has gone well. The integration has gone well. The systems have been integrated. And then we pick up on the growth trajectory, which was the reason we would have acquired these businesses.

Brian Tanquilut

That makes a lot of sense. And then as I think about the O&P industry, it seems like you guys have seen some recovery. How do you think things stand in terms of you gaining market share? And then investors have been focused on some of the data points we’re hearing out of the manufacturers. So, I guess if I may ask, how do you think the industry’s numbers or maybe some of the manufacturers numbers spike to yours or why wouldn’t they? Is it a sign of market share gains? And just any kind of differentiation that Hanger has at this point?

Vinit Asar

Sure. Yes. I think it’s two different pieces. So when a manufacturer reports their numbers, it’s a medical device business that they’re reporting on. So they could be losing market share or gaining market share against their competitors in the manufacturing industry. When we report our numbers, this is about the healthcare services industry and the provision of care that we’re providing. From where we sit, during the last six to nine months in this pandemic period, we know we probably picked up some market share in places where smaller O&P providers were either unable to provide care or provide care to the level that was normal for them. So referral sources that reached out to us to provide the care in their absence. So it’s kind of an apples and oranges if a manufacturer reports results, I would be cautious in trying to correlate the two things because we’re in the service provision, and the manufacturers are probably losing share or gaining share against their competitors.

Brian Tanquilut

Got you. And then the last question for me, Tom, just thinking about the prosthetics volume or prosthetic same-store comment on Q3. Any color you can share with us in terms of what the volumes look like? Is that apple one-to-one, essentially flat same-store decline compared to the second quarter or is there – any color you could share with us on the makeup of your prosthetics business?

Thomas Kiraly

Sure, Brian. I think that’s a good question. When you look – I think you recall back in May, when we had completed the first quarter and shared the results of the first quarter, second quarter did benefit from some additional volume that fell over from the first quarter. Now even with that, second quarter underlying prosthetic volume was down about 13%. But if you look at the mix of that volume in the second quarter, it was more of a higher acuity cases, the ones that patients that were more trauma-focused that would qualify for higher-end devices. When you look at what occurred from Q2 to Q3, we saw volumes actually pick up. And so we were only down 8% in volumes in Q3 on prosthetics as compared to 13% in Q2, and the mix of devices was more normal. It included a much bigger vascular component. And our theory is that we saw more vascular patients in Q3 as those patients became more comfortable coming and seeing their provider in the COVID environment.

Brian Tanquilut

Got you. All right. Thanks, guys.

Vinit Asar

Thanks, Brian.


And our next question will be from Larry Solow with CJS Securities. Please go ahead.

Larry Solow

Great. Thanks. Good morning. Just a couple of follow ups to Brian’s questions. I guess first question is just on the – I know your plan is to – you plan to bring back all the – unwind all the furloughs and bring back all the costs. Any hesitation to that being – clearly revenues are – and volumes are not going to get back to pre-pandemic levels probably for at least another two, three quarters I think at best and perhaps probably longer than that. So is there any hesitation for that or is there an ability to be nimble on that and maybe perhaps unwind a little bit again, if need be?

Vinit Asar

Yes. Thanks, Larry, for that question. Really no hesitation in the actions that we’ve taken so far. Clearly, we’re watching to see what happens as a result of this most current resurgence in infections. If you think back, a large part of our volumes were affected in the April, May timeframe – March, April, May timeframe, primarily because of the shelter in place orders and the shutdowns. That affected our volumes more than the fact that there are infections in place. So we’re watching that. As long as there’s no large shelter in places or shutdowns, we believe this is the right thing to do, bring back our people also because there has been a large part of our clinicians that have been working tremendous hours and the work that has to go in to treat these patients. And after every patient, we have to clean the clinic and then clean the patient room, bring in the next patient. So just a lot of stress, a lot of workload. And so bringing back some of these furloughed employees and restoring the salaries does help the morale. It certainly helps the well-being of our people as well, so they can take care of that next patient. So in summary, I guess, as long as there’s no large shelter in place type issues that we experienced in April and May, we believe this is the right thing to do. But we’ve demonstrated that we can be nimble as needed.

Larry Solow

Right. And it does sound like – certainly, results have been at least from the onside of the pandemic better than feared and clearly demonstrated a resilience certainly on the prosthetic side. And it sounds like – and inevitably, I guess a little bit of a shift more on the orthotic side, even shows that there’s even some of these patients will inevitably get back into clinic if need be. How about just switching gears real fast on the – you discussed on the distribution side. How about just on the therapeutic side, pressure on hospitals and whatnot? I know it’s a small piece of your business, but it’s still somewhat of a material piece. And it also drives a little bit of a cash outflow to a pretty good cash inflow story. So any updates on that piece of the business and how that’s been through the pandemic?

Vinit Asar

Sure. We’re actually pretty pleased with the therapeutic solutions part of our business despite the difficult environment, the skilled nursing facilities they’re in. Our team has really enhanced the value proposition. They’ve been hosting webinars for their customers, enhance some of the product offerings. So we feel that they’ve been pretty stable compared to what the skilled nursing facilities have been seeing. We know there’s a drop in census, maybe of a temporary nature, for the next quarter or two, but I think the therapeutic solutions business has been more stable than perhaps the rest of the industry from a volume perspective.

Thomas Kiraly

Yes. And Larry, let me just add a little bit of context too. If you look at the revenue decline on that business, it actually was certainly affected by COVID, but it was only down about 6.6%, which was modest. It’s literally down about 800,000 in revenue against the prior year quarter. From a cash flow standpoint, just to clarify, it actually is a positive free cash flow and positive EBITDA to the business. So it’s not a cash flow drain. And in fact, we’ve been very pleased with the management team at that business this year in the way that they’ve handled the pandemic and managed their earnings.

Larry Solow

Got you. And then just last question on the acquisitions that you’ve touched on. Do you see – without getting specific as the pandemic has evolved, have you seen an increasing amount of opportunities when there are other sellers out there more willing, less willing to sell as time has progressed?

Vinit Asar

Yes. Certainly, there are sellers out there. And I would say the pipeline is pretty robust, but we’re also being very disciplined and discriminating on the types of businesses that we’re bringing in and speaking to. There are some very good businesses out there that we’ve been speaking to, we’re very encouraged by. And on the flipside, there are some businesses that need to strengthen their documentation and things like that. So the pipeline is full, and we’re in a pretty good position to be able to determine which are the assets – which are the teams that we want to bring in versus not.

Larry Solow

Got it. Great. Thanks. I appreciate the color.

Vinit Asar

Thanks, Larry.


[Operator Instructions]. Ladies and gentlemen, this concludes our question-and-answer session and thus concludes today’s call. Thank you for joining Hanger’s third quarter 2020 earnings conference call. You may now disconnect.

Be the first to comment

Leave a Reply

Your email address will not be published.